NewAmsterdam Pharma Valuation
| NAMS Stock | 20.20 0.08 0.40% |
At this time, the firm appears to be undervalued. NewAmsterdam Pharma secures a last-minute Real Value of USD22.69 per share. The latest price of the firm is USD20.2. Our model forecasts the value of NewAmsterdam Pharma from analyzing the firm fundamentals such as Operating Margin of (0.86) %, return on equity of -0.47, and Shares Outstanding of 92.39 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting NewAmsterdam Pharma's valuation include:
Price Book 4.9063 | Enterprise Value 1.4 B | Enterprise Value Ebitda 27.6291 | Price Sales 55.3314 | Enterprise Value Revenue 42.763 |
Undervalued
Today
Please note that NewAmsterdam Pharma's price fluctuation is not too volatile at this time. Calculation of the real value of NewAmsterdam Pharma is based on 3 months time horizon. Increasing NewAmsterdam Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the NewAmsterdam stock is determined by what a typical buyer is willing to pay for full or partial control of NewAmsterdam Pharma. Since NewAmsterdam Pharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of NewAmsterdam Stock. However, NewAmsterdam Pharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 20.2 | Real 22.69 | Target 25.16 | Hype 20.46 | Naive 19.45 |
The intrinsic value of NewAmsterdam Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence NewAmsterdam Pharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of NewAmsterdam Pharma helps investors to forecast how NewAmsterdam stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of NewAmsterdam Pharma more accurately as focusing exclusively on NewAmsterdam Pharma's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use NewAmsterdam Pharma's intrinsic value based on its ongoing forecasts of NewAmsterdam Pharma's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against NewAmsterdam Pharma's closest peers.
NewAmsterdam Pharma Cash |
|
NewAmsterdam Valuation Trend
NewAmsterdam Pharma's real value is important for investors to make better decisions and a more accurate overall view of NewAmsterdam Pharma's financial worth over time. Using both NewAmsterdam Pharma's enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
NewAmsterdam Pharma Total Value Analysis
NewAmsterdam Pharma is now expected to have valuation of 1.44 B with market capitalization of 2.29 B, debt of 60 K, and cash on hands of . Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the NewAmsterdam Pharma fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.44 B | 2.29 B | 60 K |
NewAmsterdam Pharma Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. NewAmsterdam Pharma has an asset utilization ratio of 3.68 percent. This implies that the Company is making USD0.0368 for each dollar of assets. An increasing asset utilization means that NewAmsterdam Pharma is more efficient with each dollar of assets it utilizes for everyday operations.NewAmsterdam Pharma Ownership Allocation
NewAmsterdam Pharma maintains a total of 92.39 Million outstanding shares. The majority of NewAmsterdam Pharma outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in NewAmsterdam Pharma to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in NewAmsterdam Pharma. Please pay attention to any change in the institutional holdings of NewAmsterdam Pharma as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.NewAmsterdam Pharma Profitability Analysis
The company reported the previous year's revenue of 12.76 M. Net Loss for the year was (160.27 M) with profit before overhead, payroll, taxes, and interest of 0.About NewAmsterdam Pharma Valuation
The stock valuation mechanism determines NewAmsterdam Pharma's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of NewAmsterdam Pharma based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of NewAmsterdam Pharma. We calculate exposure to NewAmsterdam Pharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of NewAmsterdam Pharma's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 12.8 M | 12.1 M | |
| Pretax Profit Margin | (12.56) | (13.18) | |
| Operating Profit Margin | (12.99) | (13.63) | |
| Net Loss | (13.86) | (14.56) |
NewAmsterdam Pharma Growth Indicators
Investing in growth stocks can be very risky. If the company such as NewAmsterdam Pharma does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 82.2 M |
NewAmsterdam Pharma Current Valuation Indicators
NewAmsterdam Pharma's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final NewAmsterdam Pharma's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as NewAmsterdam Pharma, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use NewAmsterdam Pharma's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes NewAmsterdam Pharma's worth.Additional Tools for NewAmsterdam Stock Analysis
When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.